Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 20 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression. sclerotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 10 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cytarabine, quantity: 4000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

Keňa - angličtina - Pharmacy and Poisons Board

macrogol, sodium chloride, sodium bicarbonate,… - powder for oral solution - macrogol 3350 13.125g sodium chloride 350.7mg… - macrogol combinations

Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

maruishi pharmaceutical. co., ltd. - macrogol ointment - white ointment

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dendy pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - solution, powder for - excipient ingredients: - decrease/reduce/relieve constipation ; aperient/laxative ; helps reduce occurrence of constipation

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 6562.5 mg; sodium bicarbonate, quantity: 89.25 mg; potassium chloride, quantity: 23.3 mg; sodium chloride, quantity: 175.35 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation and treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

key pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - powder - excipient ingredients: - for effective relief from constipation and treatment of chronic constipation. softens stools.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - macrogol 3350 13.125 g;  ;  ; potassium chloride 0.0466 g; sodium bicarbonate 0.1785 g; sodium chloride 0.3507 g - powder for oral solution - 13.8 g - active: macrogol 3350 13.125 g     potassium chloride 0.0466 g sodium bicarbonate 0.1785 g sodium chloride 0.3507 g excipient: colloidal silicon dioxide lemon lime flavour- me 170 orange flavour 301768 saccharin sodium - for the relief from constipation, treatment of chronic constipation. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by physical examination of abdomen and rectum.